• If you are wondering whether Veradermics’ current share price lines up with its underlying value, this article breaks down what the numbers may indicate about the stock.
• Veradermics recently closed at US$107.85, with returns of 8.9% over 7 days, 90.2% over 30 days and 185.7% year to date. This puts the current price action firmly in focus for valuation-minded investors.
• Recent coverage around Veradermics has centered on its position within the Pharmaceuticals industry and how investors are pricing its prospects relative to peers. This context matters because sentiment can move the stock away from what standard valuation models might suggest is a reasonable range.
• Even after this strong run, Veradermics currently has a value score of 2/6. The sections ahead will walk through different valuation approaches and then conclude with a broader way to think about value that goes beyond a single score.

Veradermics scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Veradermics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today’s dollars, aiming to estimate what the entire business might be worth right now.

For Veradermics, the model used is a 2 Stage Free Cash Flow to Equity framework based on cash flow projections in US$. The latest twelve month free cash flow is a loss of $71.626 million. Analyst inputs cover the next few years, such as projections of $69 million and $95.5 million in annual free cash flow losses for 2026 and 2027, with discounted values of $64.421 million and $83.245 million. Further out, Simply Wall St extrapolates the path of free cash flow, with projected free cash flow of $962.163 million in 2035, discounted to $484.205 million today.

Adding all projected and discounted cash flows together gives an estimated intrinsic value of $382.79 per share. Compared with the recent share price of $107.85, this DCF output suggests Veradermics is around 71.8% undervalued on these assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Veradermics is undervalued by 71.8%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Veradermics Price vs Book

For profitable companies, price based multiples are a quick way to gauge what investors are paying for each unit of fundamentals. Price to book, or P/B, is particularly useful for Pharmaceuticals stocks where the balance sheet, including cash and intangible assets, carries important information about downside risk and capital intensity.

In general, higher growth expectations or lower perceived risk can support a higher “normal” P/B ratio. Slower growth or higher risk tends to justify a lower multiple. Veradermics currently trades on a P/B of 36.15x, compared with the Pharmaceuticals industry average of 2.66x and a peer average of 25.05x, so the stock is pricing in a much richer valuation than these broad benchmarks.

Simply Wall St’s proprietary Fair Ratio aims to estimate what P/B investors might expect for Veradermics after accounting for factors such as its earnings growth profile, industry, profit margins, market cap and specific risks. This tends to be more tailored than a simple comparison against peers or industry averages, which treat very different companies as if they should trade at similar levels. Because a Fair Ratio is not available here, it is not possible to say whether Veradermics is overvalued or undervalued using this framework alone.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Veradermics Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so meet Narratives, a simple framework on Simply Wall St’s Community page that lets you spell out your story for Veradermics, link that story to specific assumptions about future revenue, earnings and margins, translate those into a financial forecast and fair value, compare that fair value with the current share price to decide whether the stock looks attractive or expensive, and then see the Narrative update as new news or earnings are added. One investor might build a Narrative that supports a very high fair value for Veradermics because of strong expectations for its Pharmaceuticals opportunity, while another might set a much lower fair value based on more cautious forecasts and risk assumptions.

Do you think there's more to the story for Veradermics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.